Neuroprotection and Enhancement of Neurite Outgrowth With Small Molecular Weight Compounds From Screens of Chemical Libraries

International Review of Neurobiology

Volumn 77, Issue , 2007, Pages 247-289

  Dwyer, Donard S ^a   Dickson, Addie ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845469017     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(06)77008-8     Document Type: Review

References (217)

1. Allen S.J., and Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin. Sci. 110 (2006) 175-191
2. Ames III A. CNS energy metabolism as related to function. Brain Res. Brain Res. Rev. 34 (2000) 42-68
3. Angeletti P.U., Liuzzi A., Levi-Montalcini R., and Attardi D.G. Effect of a nerve growth factor on glucose metabolism by sympathetic and sensory nerve cells. Biochim. Biophys. Acta 90 (1964) 445-450
4. Angelucci F., Brene S., and Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 10 (2005) 345-352
5. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: What went wrong, what went right, and what does the future hold?. Int. Rev. Neurobiol. 50 (2002) 393-413
6. Appel S.H., and Parrot B.L. Hexose monophosphate pathway in synapses. J. Neurochem. 17 (1970) 1619-1625
7. Ardizzone T.D., Bradley R.J., Freeman III A.M., and Dwyer D.S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 923 (2001) 87-90
8. Arnold S.E., Hyman B.T., Van Hoesen G.W., and Damasio A.R. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch. Gen. Psychiatry 48 (1991) 625-632
9. Arnold S.E., Han L.-Y., Moberg P.J., Turetsky B.I., Gur R.E., Trojanowski J.Q., and Hahn C.-G. Dysregulation of olfactory receptor neuron lineage in schizophrenia. Arch. Gen. Psychiatry 58 (2001) 829-835
10. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., and San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 65 (2004) 1335-1342
11. Astrinidis A., and Henske E.R. Tuberous sclerosis complex: Linking growth and energy signaling pathways with human disease. Oncogene 24 (2005) 7475-7481
12. Ataullakhanov F.I., and Vitvitsky V.M. What determines the intracellular ATP concentration. Biosci. Rep. 22 (2002) 501-511
13. Bai O., Wei Z., Lu W., Bowen R., Keegan D., and Li X.-M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 69 (2002) 278-283
14. Baquer N.Z., Hothersall J.S., and McClean P. Function and regulation of the pentose phosphate pathway in brain. Curr. Top. Cell Regul. 29 (1988) 265-289
15. Bartlett E.J., Brodie J.D., Simkowitz P., Schloesser R., Dewey S.L., Lindenmayer J.-P., Rusinek H., Wolkin A., Cancro R., and Schiffer W. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am. J. Psychiatry 155 (1998) 337-343
16. Beck M., Flachenecker P., Magnus T., Giess R., Reiners K., Toyka K.V., and Naumann M. Autonomic dysfunction in ALS: A preliminary study on the effects of intrathecal BDNF. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6 (2005) 100-103
17. Benes F.M., Davidson J., and Bird E.D. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch. Gen. Psychiatry 43 (1986) 31-35
18. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., and Vincent S.L. Deficits in small interneurons in prefrontal and cingulated cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 48 (1991) 996-1001
19. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: A possible linkage to dopamine. J. Neurochem. 83 (2002) 1241-1251
20. Bensimon G., and Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin. Drug Saf. 3 (2004) 525-534
21. Berridge M.V., and Tan A.S. Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: Involvement of protein phosphorylation in transporter activation. Biochem. J. 305 (1995) 843-851
22. Bertram L., and Tanzi R.E. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115 (2005) 1449-1457
23. Biagiotti E., Guidi L., Capellacci S., Ambrogini P., Papa S., Del Grande P., and Ninfali P. Glucose-6-phosphate dehydrogenase supports the functioning of the synapses in rat cerebellar cortex. Brain Res. 911 (2001) 152-157
24. Binder D.K., and Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 22 (2004) 123-131
25. Blass J.P. Glucose/mitochondria in neurological conditions. Int. Rev. Neurobiol. 51 (2002) 325-376
26. Boniece I.R., and Wagner J.A. Growth factors protect PC12 cells against ischemia by a mechanism that is independent of PKA, PKC, and protein synthesis. J. Neurosci. 13 (1993) 4220-4228
27. Bontemps F., Van den Berghe G., and Hers H.-G. Evidence for a substrate cycle between AMP and adenosine in isolated hepatocytes. Proc. Natl. Acad. Sci. USA 80 (1983) 2829-2833
28. Braceland F.J., Meduna L.J., and Vaichulis J.A. Delayed action of insulin in schizophrenia. Am. J. Psychiatry 102 (1945) 108-110
29. Brandon N.J., Handford E.J., Schurov I., Rain J.-C., Pelling M., Duran-Jimeniz B., Camargo L.M., Oliver K.R., Beher D., Shearman M.S., and Whiting P.J. Disrupted in schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: Implications for schizophrenia and other neurological disorders. Mol. Cell. Neurosci. 25 (2004) 42-55
30. Braumann T., Jastorff B., and Richter-Landsberg C. Fate of cyclic nucleotides in PC12 cell cultures: Uptake, metabolism, and effects of metabolites on nerve growth factor-induced neurite outgrowth. J. Neurochem. 47 (1986) 912-919
31. Brazil D.P., Park J., and Hemmings B.A. PKB binding proteins: Getting in on the Akt. Cell 111 (2002) 293-303
32. Brown G.C. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem. J. 284 (1992) 1-13
33. Buchsbaum M.S., Nuechterlein K.H., Haier R.J., Wu J., Sicotte N., Hazlett E., Asarnow R., Potkin S., and Guich S. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br. J. Psychiatry 156 (1990) 216-227
34. Buchsbaum M.S., Potkin S.G., Marshall J.F., Lottenberg S., Teng C., Heh C.W., Tafalla R., Reynolds C., Abel L., Plon L., and Bunney Jr. W.E. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 6 (1992) 155-163
35. Burde R., Dippel E., and Seifert R. Receptor-independent G protein activation may account for the stimulatory effects of first-generation H1-receptor antagonists in HL-60 cells, basophils, and mast cells. Biochem. Pharmacol. 51 (1996) 125-131
36. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 29 (2004) 18-24
37. Chen W.G., Chang Q., Lin Y., Meissner A., West A.E., Griffith E.C., Jaenisch R., and Greenberg M.E. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302 (2003) 885-889
38. Chen W.S., Xu P.-Z., Gottlob K., Chen M.-L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., Kadowaki T., and Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes Dev. 15 (2001) 2203-2208
39. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw III E.B., Kaestner K.H., Bartolomei M.S., Shulman G.I., and Birnbaum M.J. Insulin resistance and a diabetes-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292 (2001) 1728-1731
40. Cho H., Thorvaldsen J.L., Chu Q., Feng F., and Birnbaum M.J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276 (2001) 38349-38352
41. Chowdari K.V., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., Deshpande S.N.T., Ferrell R.E., Middleton F.A., Devlin B., Levitt P., Lewis D.A., et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mol. Genet. 11 (2002) 1373-1380
42. Chugani D.C., Sundram B.S., Behen M., Lee M.L., and Moore G.J. Evidence of altered energy metabolism in autistic children. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 635-641
43. Clapham D.E., and Neer E.J. G protein βγ subunits. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 167-203
44. Cohen S. Purification and metabolic effects of a nerve growth-promoting protein from snake venom. J. Biol. Chem. 234 (1959) 1129-1137
45. Cooper J.R., and Pincus J.H. The role of thiamine in the nervous system. Neurochem. Res. 4 (1979) 223-239
46. Culmsee C., Monnig J., Kemp B.E., and Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 17 (2001) 45-58
47. Dago L., Bonde C., Peters D., Moller A., Bomholt S.F., Hartz J.B., Meyer M., Drejer J., and Gronborg M. NS 1231, a novel compound with neurotrophic-like effects in vitro and in vivo. J. Neurochem. 81 (2002) 17-24
48. Dago L., Peters D., Meyer M., Hartz B., Kruse V., Drejer J., and Gronborg M. NS-417, a novel compound with neurotrophic-like effects. Neurochem. Res. 27 (2002) 107-111
49. Davis J.O., and Bracha H.S. Famine and schizophrenia: First trimester malnutrition or second trimester beriberi?. Biol. Psychiatry 40 (1996) 1-3
50. Deckwerth T.L., and Johnson Jr. E.M. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J. Cell Biol. 123 (1993) 1207-1222
51. Delgado-Esteban M., Almeida A., and Bolanos J.P. D-Glucose prevents glutathione oxidation and mitochondrial damage after glutamate receptor stimulation in rat cortical primary neurons. J. Neurochem. 75 (2000) 1618-1624
52. de Rooij J., Zwartkruis F.J., Verhaijen M.H., Cool R.H., Nijman S.M.B., Wittinghofer A., and Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396 (1998) 474-477
53. Dobyns W.B., Reiner O., Carrozzo R., and Ledbetter D.H. Lissencephaly: A human brain malformation associated with deletion of the LIS1 gene located at chromosome 17p13. JAMA 270 (1993) 2838-2842
54. Duman R.S. Synaptic plasticity and mood disorders. Mol. Psychiatry 7 Suppl. 1 (2002) S29-S34
55. Dwyer D.S., and Bradley R.J. Chemical properties of alcohols and their protein binding sites. Cell. Mol. Life Sci. 57 (2000) 265-275
56. Dwyer D.S., and Donohoe D. Induction of hyperglycemia in mice by atypical antipsychotic drugs. Pharmacol. Biochem. Behav. 75 (2003) 255-261
57. Dwyer D.S., Liu Y., and Bradley R.J. Ethanol-sensitive variant of the PC12 neuronal cell line: Sensitivity to alcohol is associated with increased cell adhesion and decreased glucose accumulation. J. Cell. Physiol. 178 (1999) 93-101
58. Dwyer D.S., Pinkofsky H.B., Liu Y., and Bradley R.J. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 69-80
59. Dwyer D.S., Bradley R.J., Kablinger A.S., and Freeman III A.M. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann. Clin. Psychiatry 13 (2001) 103-113
60. Dwyer D.S., Ardizzone T.D., and Bradley R.J. Psychoactive drugs affect glucose transport and the regulation of glucose metabolism. Int. Rev. Neurobiol. 51 (2002) 503-530
61. Dwyer D.S., Vannucci S.J., and Simpson I.A. Expression, regulation, and functional role of glucose transporters (GLUTs) in brain. Int. Rev. Neurobiol. 51 (2002) 159-188
62. Dwyer D.S., Lu X.-H., and Bradley R.J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res. 971 (2003) 31-39
63. Dwyer D.S., Lu X.-H., and Freeman III A.M. Neuronal glucose metabolism and schizophrenia: Therapeutic prospects?. Expert Rev. Neurother. 3 (2003) 29-40
64. Dzeja P.P., Zeleznikar R.J., and Goldberg N.D. Adenylate kinase: Kinetic behavior in intact cells indicates that it is integral to multiple cellular processes. Mol. Cell. Biochem. 184 (1998) 169-182
65. Easton R.M., Cho H., Roovers K., Shineman D.W., Mizrahi M., Forman M.S., Lee V.M., Szabolcs M., de Jong R., Oltersdorf T., Ludwig T., Efstratiadis A., et al. Role for Akt3/Protein kinase Bγ in attainment of normal brain size. Mol. Cell. Biol. 25 (2005) 1869-1878
66. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., and Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
67. Feinberg I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?. J. Psychiatr. Res. 17 (1982) 319-334
68. Feinberg J.F. The Wernicke-Korsakoff syndrome. Am. Fam. Physician 22 (1980) 129-133
69. Feldman H.H., Van Baelen B., Kavanagh S.M., and Torfs K.E. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: A 12-month analysis. Alzheimer Dis. Assoc. Disord. 19 (2005) 29-36
70. Feng Y., Olson E.C., Stukenberg P.T., Flanagan L.A., Kirschner M.W., and Walsh C.A. LIS1 regulates CNS lamination by interacting with mNudE, a central component of the centrosome. Neuron 28 (2000) 665-679
71. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., et al. Global prevalence of dementia: A Delphi consensus study. Lancet 366 (2005) 2112-2117
72. Freeman H., Looney J.M., Hoskins R.G., and Dyer C.G. Results of insulin and epinephrine tolerance tests in schizophrenic patients and in normal subjects. Arch. Neurol. Psychiatry 49 (1943) 195-203
73. Freeman R. Human studies of recombinant human nerve growth factor and diabetic peripheral neuropathy. Eur. Neurol. 41 Suppl. 1 (1999) 20-26
74. Ghosh M., Peterson Y.K., Lanier S.M., and Smrcka A.V. Receptor- and nucleotide exchange-independent mechanisms for promoting G protein subunit dissociation. J. Biol. Chem. 278 (2003) 34747-34750
75. Glantz L.A., and Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry 54 (1997) 943-952
76. Gonatas N.K., and Moss A. Pathologic axons and synapses in human neuropsychiatric disorders. Hum. Pathol. 6 (1975) 571-581
77. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15 (2001) 1406-1418
78. Goossens V., Grooten J., and Fiers W. The oxidative metabolism of glutamine. J. Biol. Chem. 271 (1996) 192-196
79. Gordon P.H. Advances in clinical trials for amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 5 (2005) 48-54
80. Greenough W.T., Larson J.R., and Withers G.S. Effects of unilateral and bilateral training in a reaching task on dendritic branching of neurons in the rat motor-sensory forelimb cortex. Behav. Neural Biol. 44 (1985) 301-314
81. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., and O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93 (2005) 105-117
82. Gu M., Irvani M., Cooper J.M., King D., Jenner P., and Schapira A.H. Pramipexole protects against apoptotic cell death by non-dopaminergic neurons. J. Neurochem. 91 (2004) 1075-1081
83. Gupta A., Ho D.Y., Brooke S., Franklin L., Roy M., McLaughlin J., Fink S.L., and Sapolsky R.M. Neuroprotective effects of an adenoviral vector expressing the glucose transporter: A detailed description of the mediating cellular events. Brain Res. 908 (2001) 49-57
84. Hageluken A., Grunbaum L., Nurnberg B., Harhammer R., Schunack W., and Seifert R. Lipophilic β-adrenoceptor antagonists and local anesthetics are effective direct activators of G-proteins. Biochem. Pharmacol. 47 (1994) 1789-1795
85. Hajduch E., Litherland G.J., and Hundal H.S. Protein kinase B (PKB/Akt)-a key regulator of glucose transport?. FEBS Lett. 492 (2001) 199-203
86. Hardie D.G., Scott J.W., Pan D.A., and Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546 (2003) 113-120
87. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
88. Hawkins R.A., Williamson D.H., and Krebs H.A. Ketone-body utilization by adult and suckling rat brain in vivo. Biochem. J. 122 (1971) 13-18
89. Heininger K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev. Neurosci. 11 (2000) 213-328
90. Henderson D.C., and Ettinger E.R. Schizophrenia and diabetes. Int. Rev. Neurobiol. 51 (2002) 481-501
91. Hertz L., and Dienel G.A. Energy metabolism in the brain. Int. Rev. Neurobiol. 51 (2002) 1-102
92. Hickmott P.W., and Ethell I.M. Dendritic plasticity in the adult neocortex. Neuroscientist 12 (2006) 16-28
93. Higashijima T., and Ross E.M. Mapping of the mastoparan-binding site of G proteins. J. Biol. Chem. 266 (1991) 12655-12661
94. o by mastoparan, related amphiphilic peptides, and hydrophobic amines. J. Biol. Chem. 265 (1990) 14176-14186
95. Hock C., Heese K., Hulette C., Rosenberg C., and Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 57 (2000) 846-851
96. Hollinger S., and Hepler J.R. Cellular regulation of RGS proteins: Modulators and integrators of G protein signaling. Pharmacol. Rev. 54 (2002) 527-559
97. Honegger P., Braissant O., Henry H., Boulat O., Bachmann C., Zurich M.-G., and Pardo B. Alteration of amino acid metabolism in neuronal aggregate cultures exposed to hypoglycaemic conditions. J. Neurochem. 81 (2002) 1141-1151
98. Hothersall J.S., Greenbaum A.L., and McLean P. The functional significance of the pentose phosphate pathway in synaptosomes: Protection against peroxidative damage by catecholamines and oxidants. J. Neurochem. 39 (1982) 1325-1332
99. Hulshoff Pol H.E., Hoek H.W., Susser E., Brown A.S., Dingemans A., Schnack H.G., van Haren N.E., Pereira Ramos L.M., Gispen-de Wied C.C., and Kahn R.S. Prenatal exposure to famine and brain morphology in schizophrenia. Am. J. Psychiatry 157 (2000) 1170-1172
100. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., and Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
101. Ingvar D.H., and Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiat. Scand. 50 (1974) 425-462
102. Inoki K., Zhu T., and Guan K.-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
103. Inouye S., Seo M., Yamada Y., and Nakazawa A. Increase of adenylate kinase isozyme 1 protein during neuronal differentiation in mouse embryonal carcinoma P19 cells and in rat brain primary cultured cells. J. Neurochem. 71 (1998) 125-133
104. Inouye S., Yamada Y., Miura K., Suzuki H., Kawata K., Shinoda K., and Nakazawa A. Distribution and developmental changes of adenylate kinase isozymes in the rat brain: Localization of adenylate kinase 1 in the olfactory bulb. Biochem. Biophys. Res. Commun. 254 (1999) 618-622
105. Ishijima Y., Shimada N., Fukuda M., Miyazaki H., Orlov N.Y., Orlova T.G., Yamada T., and Kimura N. Overexpression of nucleoside diphosphate kinases induces neurite outgrowth and their substitution to inactive forms leads to suppression of nerve growth factor- and dibutyryl cyclic AMP-induced effects in PC12D cells. FEBS Lett. 445 (1999) 155-159
106. Jiang X.M., Ohnishi A., Yamamoto T., Murai Y., Awaya A., and Ikeda M. The effect of MS-818, a pyrimidine compound, on the regeneration of peripheral nerve fibers of mice after a crush injury. Acta Neuropathol. 90 (1995) 130-134
107. Kaibuchi K., Kuroda S., and Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem. 68 (1999) 459-486
108. Kalaria R.N., and Harik S.I. Reduced glucose transport at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J. Neurochem. 53 (1989) 1083-1088
109. Kan O., Baldwin S., and Whetton A. Apoptosis is regulated by the rate of glucose transport in an interleukin-3-dependent cell line. J. Exp. Med. 180 (1994) 917-923
110. Kawasaki H., Springett G.M., Mochizuki N., Toki S., Nakaya M., Matsuda M., Housman D.E., and Graybiel A.M. A family of cAMP-binding proteins that directly activate Rap1. Science 282 (1998) 2275-2279
111. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Rock S.L., Woolson S., Tohen M., Tollefson G.D., Sanger T.M., Lieberman J.A.,, and and HGDH Research Group. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry 59 (2006) 97-105
112. Kholmanskikh S.S., Koeller H.B., Wynshaw-Boris A., Gomez T., Letourneau P.C., and Ross M.E. Calcium-dependent interaction of Lis1 with IQGAP1 and Cdc42 promotes neuronal motility. Nat. Neurosci. 9 (2006) 50-57
113. i interaction sites with guanine nucleotide dissociation inhibitor activity. J. Biol. Chem. 276 (2001) 29275-29281
114. Klebe G. Recent developments in structure-based drug design. J. Mol. Med. 78 (2000) 269-281
115. Kodama M., Fujioka T., and Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry 56 (2004) 570-580
116. Kolb B., and Whishaw I.Q. Brain plasticity and behavior. Annu. Rev. Psychol. 49 (1998) 43-64
117. Kovacevic Z., and McGivan J.D. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol. Rev. 63 (1983) 547-605
118. Krishnan K.S., Rikhy R., Rao S., Shivalkar M., Mosko M., Narayanan R., Etter P., Estes P.S., and Ramaswami M. Nucleoside diphosphate kinase, a source of GTP, is required for dynamin-dependent synaptic vesicle recycling. Neuron 30 (2001) 197-210
119. Laird E.R., and Blake J.F. Structure-based generation of viable leads from small combinatorial libraries. Curr. Opin. Drug Discov. Devel. 7 (2004) 354-359
120. Law A.J., Hutchinson L.J., Burnet P.W., and Harrison P.J. Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex. J. Neurosci. Res. 76 (2004) 376-382
121. Lawlor M.A., and Alessi D.R. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses?. J. Cell Sci. 114 (2001) 2903-2910
122. Lawrence M., Ho D., Dash R., and Sapolsky R. Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss. Proc. Natl. Acad. Sci. USA 92 (1995) 7247-7251
123. Lawrence M., Sun G., Kunis T., Saydam T., Dash R., Ho D., Sapolsky R., and Steinberg G. Overexpression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke. J. Cerebr. Blood Flow Metab. 16 (1996) 181-185
124. LeBlanc A.C. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr. Alzheimer Res. 2 (2005) 389-402
125. Levi-Montalcini R., and Angeletti P.U. Nerve growth factor. Physiol. Rev. 48 (1968) 534-569
126. Lewis D.A., and Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25 (2002) 409-432
127. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A.,, and and CATIE investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
128. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62 (2005) 361-370
129. Lo Nigro C., Chong S.S., Smith A.C., Dobyns W.B., Carrozzo R., and Ledbetter D.H. Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome. Hum. Mol. Genet. 6 (1997) 157-164
130. Lowenstein J.M. Ammonia production in muscle and other tissues: The purine nucleotide cycle. Physiol. Rev. 52 (1972) 382-414
131. Lu X.-H., and Dwyer D.S. Second generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/Akt, ERK and pertussis toxin-sensitive pathways. J. Mol. Neurosci. 27 (2005) 43-64
132. Lu X.-H., Bradley R.J., and Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res. 1011 (2004) 58-68
133. Maher F., Vannucci S.J., and Simpson I.A. Glucose transporter proteins in brain. FASEB J. 8 (1994) 1003-1011
134. Maher K.R., Harper J.F., Macleay A., and King M.G. Peculiarities in the endocrine response to insulin stress in early infantile autism. J. Nerv. Ment. Dis. 161 (1975) 180-184
135. Mauer I., Zierz S., and Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 48 (2001) 125-136
136. McGeer E.G., and McGeer P.L. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 19 (2005) 31-37
137. McGlashan T.H., and Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 57 (2000) 637-648
138. McKenna M.C., Stevenson J.H., Huang X., and Hopkins I.B. Differential distribution of the enzymes glutamate dehydrogenase and aspartate aminotransferase in cortical synaptic mitochondria contributes to metabolic compartmentation in cortical synaptic terminals. Neurochem. Int. 37 (2000) 229-241
139. Meininger V., Bensimon G., Bradley W.R., Brooks B., Douillet P., Eisen A.A., Lacomblez L., Leigh P.N., and Robberecht W. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5 (2004) 107-117
140. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
141. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., and Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 22 (2002) 2718-2729
142. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor C.A., Semple C.A., Devon R.S., Clair D.M., Muir W.J., Blackwood D.H., and Porteous D.J. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9 (2000) 1415-1423
143. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., Thomson P.A., Hill E.V., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005) 1187-1191
144. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., and Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry 6 (2001) 293-301
145. Moberg P.J., Agrin R., Gur R.E., Gur R.C., Turetsky B.I., and Doty R.L. Olfactory dysfunction in schizophrenia: A qualitative and quantitative review. Neuropsychopharmacology 21 (1999) 325-340
146. Mohr E., Nair N.P., Sampson M., Murtha S., Belanger G., Pappas B., and Mendis T. Treatment of Alzheimer's disease with sabeluzole: Functional and structural correlates. Clin. Neuropharmacol. 20 (1997) 338-345
147. Moises H.W., Zoega T., and Gottesman I.I. The glial growth factors deficiency and synaptic stabilization hypothesis of schizophrenia. BMC Psychiatry 2 (2002) 8-21
148. Moley K.H., and Mueckler M.M. Glucose transport and apoptosis. Apoptosis 5 (2000) 99-105
149. Molina V., Sanz J., Benito C., and Palomo T. Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia. Int. Clin. Psychopharmacol. 19 (2004) 221-228
150. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., and Manji H.K. Lithium-induced increase in human brain grey matter. Lancet 356 (2000) 1241-1242
151. +-dependent malic enzyme. J. Biol. Chem. 259 (1984) 6215-6221
152. Morelli A., Grasso M., and Calissano P. Effect of nerve growth factor on glucose utilization and nucleotide content of pheochromocytoma cells (clone PC12). J. Neurochem. 47 (1986) 375-381
153. Morris A.J., Rudge S.A., Mahlum C.E., and Jenco J.M. Regulation of phosphoinositide-3-kinase by G protein βγ subunits in a rat osteosarcoma cell line. Mol. Pharmacol. 48 (1995) 532-539
154. i alpha2. Nature 379 (1996) 840-844
155. αi2-specific antisense RNA in vivo inhibits neonatal growth. Science 260 (1993) 991-995
156. Mueser K.T., and McGurk S.R. Schizophrenia. Lancet 363 (2004) 2063-2072
157. Mukherjee S., Schnur D.B., and Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1 (1989) 495
158. Neul J.L., and Zoghbi H.Y. Rett syndrome: A prototypical neurodevelopmental disorder. Neuroscientist 10 (2004) 118-128
159. Newcomer J.W., Craft S., Fucetola R., Moldin S.O., Selke G., Paras L., and Miller R. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr. Bull. 25 (1999) 321-335
160. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., and Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 59 (2002) 337-345
161. Niethammer M., Smith D.S., Ayala R., Peng J., Ko J., Lee M.-S., Morabito M., and Tsai L.-H. NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron 28 (2000) 697-711
162. Ninfali P., Guidi L., Aluigi G., Biagotti E., and Del Grande P. High glucose-6-phosphate dehydrogenase activity contributes to the structural plasticity of periglomerular cells in the olfactory bulb of adult rats. Brain Res. 819 (1999) 150-154
163. Nozawa Y., Sakai N., Matsumoto K., and Mizoue K. A novel neuritogenic compound, NGA0187. J. Antibiot. 55 (2002) 629-634
164. Odagaki Y., Nishi N., and Koyama T. Receptor-mediated and receptor-independent activation of G-proteins in rat brain membranes. Life Sci. 62 (1998) 1537-1541
165. Offermanns S. New insights into the in vivo function of heterotrimeric G-proteins through gene deletion studies. Naunyn Schmiedebergs Arch. Pharmacol. 360 (1999) 5-13
166. Owen O.E., Kalhan S.C., and Hanson R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277 (2002) 30409-30412
167. Palmen S.J., van Engeland H., Hof P.R., and Schmitz C. Neuropathological findings in autism. Brain 127 (2004) 2572-2583
168. Paul J.W., Quach T.T., Duchemin A., Schrier B.K., and DaVanzo J.P. 1,1,3 Tricyano-2-amino-1-propene (Triap): A small molecule which mimics or potentiates nerve growth factor. Brain Res. Dev. Brain Res. 55 (1990) 21-27
169. Pellerin L., Pellegri G., Bittar P.G., Charnay Y., Bouras C., Martin J.L., Stella N., and Magistretti P.J. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev. Neurosci. 20 (1998) 291-299
170. Percy A.K. Clinical trials and treatment prospects. Ment. Retard. Dev. Disabil. Res. Rev. 8 (2002) 106-111
171. Plas D.R., and Thompson C.B. Akt-dependent transformation: There is more to growth than just surviving. Oncogene 24 (2005) 7435-7442
172. Rabinovitz M. The pleiotypic response to amino acid deprivation is the result of interactions between components of the glycolysis and protein synthesis pathways. FEBS Lett. 302 (1992) 113-116
173. Reiner O. LIS1: Let's interact sometimes ... (Part 1). Neuron 28 (2000) 633-636
174. Reiner O., Carrozzo R., Shen Y., Wehnert M., Faustinella F., Dobyns W.B., Caskey C.T., and Ledbetter D.H. Isolation of a Miller-Dieker lissencephaly gene containing G protein β-subunit-like repeats. Nature 364 (1993) 717-721
175. Renshaw P.F., Yurgelun-Todd D.A., Wei H., Charles H.C., Tohen M., Sharma T., Zipursky R.B., Kahn R., Gur R.E., Green A.I., McEvoy J.P., Perkins D.O., et al. Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis. Biol. Psychiatry 53 (2003) 67S
176. Riese U., Ziegler E., and Hamburger M. Militarinone A induces differentiation in PC12 cells via MAP and Akt kinase signal transduction pathways. FEBS Lett. 577 (2004) 455-459
177. Rosoklija G., Toomayan G., Ellis S.P., Keilp J., Mann J.J., Latov N., Hays A.P., and Dwork A.J. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: Preliminary findings. Arch. Gen. Psychiatry 57 (2000) 349-356
178. Ruigt G.S., Makkink W.K., and Konings P.N.M. SR 57746A attenuates cytostatic drug-induced reduction of neurite outgrowth in co-cultures of rat dorsal root ganglia and Schwann cells. Neurosci. Lett. 203 (1996) 9-12
179. Rumsey J.M., Duara R., Grady C., Rapoport J.L., Margolin R.A., Rapoport S.I., and Cutler N.R. Brain metabolism in autism. Resting cerebral glucose utilization rates as measured with positron emission tomography. Arch. Gen. Psychiatry 42 (1985) 448-455
180. Rutter G.A., da Silva Xavier G., and Leclerc I. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homeostasis. Biochem. J. 375 (2003) 1-16
181. Sacks W., Esser A.H., Feitel B., and Abbott K. Acetazolamide and thiamine: An ancillary therapy for chronic mental illness. Psychiatry Res. 28 (1989) 279-288
182. Sakel M. The methodical use of hypoglycemia in the treatment of psychoses. Am. J. Psychiatry 94 (1938) 111-129
183. Sanjo N., Owada K., Kobayashi T., Mizusawa H., Awaya A., and Michikawa M. A novel neurotrophic pyrimidine compound MS-818 enhances neurotrophic effects of basic fibroblast growth factor. J. Neurosci. Res. 54 (1998) 604-612
184. Saywell V., Viola A., Confort-Gouny S., Le Fur Y., Villard L., and Cozzone P.J. Brain magnetic resonance study of Mecp2 deletion effects on anatomy and metabolism. Biochem. Biophys. Res. Commun. 340 (2006) 776-783
185. Schifitto G., Yiannoutsos C., Simpson D.M., Adornato B.T., Singer E.J., Hollander H., Marra C.M., Rubin M., Cohen B.A., Tucker T., Koralnik I.J., Katzenstein D., et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 57 (2001) 1313-1316
186. Simpson I.A., Chundu K., Davies-Hill T., Honer W.G., and Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35 (1994) 546-551
187. Sofroniew M.V., Howe C.L., and Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24 (2001) 1217-1281
188. Sokoloff L. Circulation and energy metabolism in the brain. In: Siegel G.J., Albers R.W., Katzman R., and Agranoff B.W. (Eds). "Basic Neurochemistry" (1976), Little, Brown and Company, Boston 388-413
189. Strange P.G. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53 (2001) 119-133
190. Tailby C., Wright L.L., Metha A.B., and Calford M.B. Activity-dependent maintenance and growth of dendrites in adult cortex. Proc. Natl. Acad. Sci. USA 102 (2005) 4631-4636
191. 2 adrenergic receptor third intracellular loop peptide to Gβ and the amino terminus of Gα. J. Biol. Chem. 269 (1994) 27618-27624
192. Thompson P.M., Vidal C., Giedd J.N., Gochman P., Blumenthal J., Nicholson R., Toga A.W., and Rapoport J.L. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. USA 98 (2001) 11650-11655
193. Tolosa E. Advances in the pharmacological management of Parkinson disease. J. Neural Transm. Suppl. 64 (2003) 65-78
194. Tuszynski M.H., Thal L., Pay M., Salmon D.P., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. U. H. S.,. Nat. Med. 11 (2005) 551-555
195. Ujike H., and Nakata K. Genetic study of schizophrenia: New targets for therapy. Expert Rev. Neurother. 3 (2003) 41-50
196. Van den Berghe G., Bontemps F., Vincent M.F., and Van den Berghe F. The purine nucleotide cycle and its molecular defects. Prog. Neurobiol. 39 (1992) 547-561
197. Vander Heiden M.G., Plas D.R., Rathmell J.C., Fox C.J., Harris M.H., and Thompson C.B. Growth factors can influence cell growth through effects on glucose metabolism. Mol. Cell. Biol. 21 (2001) 5899-5912
198. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70 (2001) 535-602
199. Verdonk M.L., and Hartshorn M.J. Structure-guided fragment screening for lead discovery. Curr. Opin. Drug Discov. Devel. 7 (2004) 404-410
200. Volkmar F.R., and Greenough W.T. Rearing complexity affects branching of dendrites in the visual cortex of the rat. Science 176 (1972) 1445-1447
201. Wagle A., Jivraj S., Garlock G.L., and Stapleton S.R. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase. J. Biol. Chem. 273 (1998) 14968-14974
202. Waitzkin L. A survey of unknown diabetics in a mental hospital. II. Men from age fifty. Diabetes 15 (1966) 164-172
203. Wakade C.G., Mahadik S.P., Waller J.L., and Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 69 (2002) 72-79
204. Waki A., Yano R., Yoshimoto M., Sadato N., Yonekura Y., and Fujibayashi Y. Dynamic changes in glucose metabolism accompanying the expression of the neural phenotype after differentiation in PC12 cells. Brain Res. 894 (2001) 88-94
205. Wang H.D., Dunnavant F.D., Jarman T., and Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29 (2004) 1230-1238
206. Waters C., Pyne S., and Pyne N.J. The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin. Cell Dev. Biol. 15 (2004) 309-323
207. Wei Z., Bai O., Richardson J.S., and Li X.-M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 73 (2003) 364-368
208. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44 (1987) 660-669
209. Weinberger D.R., Berman K.F., and Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 43 (1986) 114-124
210. Wellmer A., Misra V.P., Sharief M.K., Kopelman P.G., and Anand P. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J. Peripher. Nerv. Syst. 6 (2001) 204-210
211. Whiteman E.L., Cho H., and Birnbaum M.J. Role of Akt/Protein kinase B in metabolism. Trends Endocrinol. Metab. 13 (2002) 444-451
212. Wolkin A., Jaeger J., Brodie J.D., Wolf A.P., Fowler J., Rotrosen J., Gomez-Mont F., and Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am. J. Psychiatry 142 (1985) 564-571
213. Wu E.H.T., and Wong Y.H. Involvement of Gi/o proteins in nerve growth factor-stimulated phosphorylation and degradation of tuberin in PC-12 cells and cortical neurons. Mol. Pharmacol. 67 (2005) 1195-1205
214. Yoshikawa H., Fueki N., Suzuki H., Sakuragawa N., and Iio M. Cerebral blood flow and oxygen metabolism in the Rett syndrome. Brain Dev. 14 Suppl. (1992) S69-S74
215. Zhang J., Zhang J., Benovic J.L., Sugai M., Weyzker R., Gout I., and Rittenhouse S.E. Sequestration of a G protein βγ subunit or ADP-ribosylation of Rho can inhibit thrombin-induced activation of phosphoinositide 3-kinases. J. Biol. Chem. 270 (1995) 6589-6594
216. Zilbovicius M., Garreau B., Samson Y., Remy P., Barthelemy C., Syrota A., and Lelord G. Delayed maturation of the frontal cortex in childhood autism. Am. J. Psychiatry 152 (1995) 248-252
217. Zoghbi H.Y. Postnatal neurodevelopmental disorders: Meeting at the synapse?. Science 302 (2003) 826-830